Previous close | 89.70 |
Open | 89.29 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 92.96 - 95.07 |
52-week range | 84.53 - 119.56 |
Volume | |
Avg. volume | 63,990 |
Market cap | N/A |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 0.16 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer